Polaryx Therapeutics, Inc. Common Stock
NASDAQ:PLYXBiotechnology
-$0.02 today
- Market cap
- $80.25M
- Beta
- 0.00
- P/E (TTM)
- -16.7
- EPS (TTM)
- -$0.14
Volume 0.02M
Average 0.34M
PLYX Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Polaryx Therapeutics, Inc. Common StockNASDAQ: PLYX
Net Income · Q4 FY2025 · quarter ended Dec 2025
Net income grows 106.8% year over year
Q4 FY2025 net income of $1.5M (cash outflow) rose 106.8% year over year. Sequentially, it rose 4.5% from the prior quarter.
Context
- Net income grew in size in 1 of the last 2 fiscal years.
What to watch
Whether net income reaches the consensus estimate of -$5.68M (-36.8%) for the fiscal year ending Dec 2026, a step up from the -70.4% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterDec 2025
- -$1.5M+4.5% QoQ
- Last fiscal yearDec 2025
- -$8.99M-70.4% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +106.8% | -81.3% | -188.1 pp |
| 1 year | -70.4% | -36.8% | +33.6 pp |
| 3-year CAGR | — | +32.4% | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- (8.99M) USD
- Year-over-year change
- +70.4%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (8.99M) | +70.4% |
| FY2024 | 2024-12-31 | (30.36M) | -703.3% |
| FY2023 | 2023-12-31 | (3.78M) | — |
Net Income vs competitors
How PLYX compares with its peers on the latest reported figures
- PLYX's FY2025 net income of $8.99M is the smallest of the 8 companies compared; the peer median is $75.32M.
- Its year-over-year change of -70.4% is the lowest of 6, against a peer median of -6.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $246.41M | -26.3% | +14.4% | 794858.1% | |
| LTM Mar 2026 | $162.08M | +206.1% | +47.5% | 1363.9% | |
| LTM Mar 2026 | $129.61M | — | +35.2% | — | |
| LTM Mar 2026 | $75.32M | -6.4% | -12.0% | 266.9% | |
| LTM Mar 2026 | $51.59M | +600.9% | +160.2% | 186.2% | |
KLRSKalaris Therapeutics Inc | LTM Mar 2026 | $44.1M | — | +41.0% | — |
| LTM Mar 2026 | $34.55M | -23.8% | -4.9% | — | |
PLYXPolaryx Therapeutics, Inc. Common Stock | FY2025 | $8.99M | -70.4% | — | — |
| Peer median (excluding PLYX) | $75.32M | -6.4% | +35.2% | 815.4% | |
Competitors are the stored peer set for PLYX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|
| Net Income | (3.78M) | (30.36M) | (8.99M) |
| Depreciation & Amortization | 0 | 0 | 0 |
| Deferred Income Tax | 0 | 0 | 0 |
| Stock-Based Compensation | 3.24M | 2.4M | 0 |
| Change in Working Capital | 369K | (621K) | 316K |
| Accounts Receivables | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 |
| Accounts Payables | (52K) | (401K) | 398K |
| Other Working Capital | 421K | (220K) | (82K) |
| Other Non-Cash Items | 0 | 26M | 4.73M |
| Operating Cash Flow | (173K) | (2.57M) | (3.94M) |
| Capital Expenditures | 0 | 0 | 0 |
| Acquisitions (Net) | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 |
| Investing Cash Flow | 0 | 0 | 0 |
| Debt Repayment | 128K | (128K) | 0 |
| Common Stock Issued | 0 | 7.32M | 4.47M |
| Common Stock Repurchased | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 |
| Other Financing Activities | 0 | 0 | 0 |
| Financing Cash Flow | 128K | 7.19M | 4.47M |
| Effect of Forex Changes | 0 | 0 | 0 |
| Net Change in Cash | (45K) | 4.62M | 522K |
| Free Cash Flow | (173K) | (2.57M) | (3.94M) |
Polaryx Therapeutics, Inc. Common Stock
NASDAQ:PLYX
Intrinsic Alpha fair value
Locked
Current Price
$1.61
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.